Trace oxidative carbon loss, reversible pentose routing and red-cell NADPH defense, then interpret enzyme results during hemolysis and transfusion.
A red cell can still make ATP while losing protection from oxidants. The pentose phosphate pathway answers a different need from glycolysis. Follow the carbon, then follow the electrons, before deciding what a normal enzyme result means.
One carbon leaves. Two reducing equivalents remain.
The pentose phosphate pathway runs in the cytosol. It shares glucose-6-phosphate, or G6P, with glycolysis. Its oxidative branch supplies NADPH, a reduced electron donor, rather than making ATP. A six-carbon starting sugar can therefore support protection or synthesis without being an ATP-producing reaction itself. [1]
G6PD, glucose-6-phosphate dehydrogenase, first oxidizes G6P to 6-phosphogluconolactone and reduces one NADP+ to NADPH. Lactonase then hydrolyzes the lactone to 6-phosphogluconate. Hydrolysis does not supply another NADPH. The next dehydrogenase, 6-phosphogluconate dehydrogenase, produces ribulose-5-phosphate, a second NADPH and carbon dioxide.
The net oxidative reaction is G6P + 2 NADP+ + H2O → ribulose-5-P + CO2 + 2 NADPH + 2 H+. The carbon accounting is six in, five retained and one released. Carbon 1 of the incoming G6P becomes CO2 in this single passage. No ATP is generated by these reactions. The pathway's alternative name, the hexose monophosphate shunt, describes this diversion of a hexose phosphate.
Predict whether a label on carbon 1 or carbon 6 remains in the pentose after one oxidative passage. Then stop the second dehydrogenase and reconsider.
The oxidative branch has a net forward direction under cellular conditions. That does not mean its remaining five carbons can never reach glycolysis. The reversible branch below can return pentose carbon to glycolytic intermediates. Distinguish reversing an oxidative reaction from taking a different route through a connected network.
NADPH use creates NADP+, the oxidized acceptor needed for further production. With adequate G6P and functional enzymes, a rise in demand can support increased oxidative flux. Capacity matters as well as demand. A deficient enzyme cannot necessarily meet a new oxidant burden simply because more NADP+ is available. [4]
If a purified preparation stops after lactonase, how many NADPH have formed?
One per G6P processed. The second reduction requires 6-phosphogluconate dehydrogenase.
Transfer. A label retained in the pentose after this first passage may be redistributed in later reactions. Single-pass labeling cannot be extended unchanged to repeated recycling or to complete glucose oxidation.
Keep the carbon. Change the shape of the supply.
Ribulose-5-P is a ketopentose. An isomerase interconverts it with the aldopentose ribose-5-P; an epimerase interconverts it with xylulose-5-P. These five-carbon sugars have different arrangements, not different carbon totals. Ribose-5-P supplies the sugar scaffold for nucleotide synthesis in cells that are making nucleotides. [1]
Transketolase transfers a two-carbon unit and requires thiamine pyrophosphate, TPP. Transaldolase transfers a three-carbon unit and does not share that TPP requirement. Both participate in reversible rearrangements. Neither is one of the NADPH-producing dehydrogenases.
Write the reactions with carbon numbers first. Xylulose-5-P plus ribose-5-P gives glyceraldehyde-3-P plus sedoheptulose-7-P through transketolase. Transaldolase then combines the seven-carbon sugar with glyceraldehyde-3-P to yield erythrose-4-P plus fructose-6-P. A second transketolase reaction combines xylulose-5-P with erythrose-4-P to yield another fructose-6-P plus glyceraldehyde-3-P. [8]
The net rearrangement is 2 xylulose-5-P + ribose-5-P ⇌ 2 fructose-6-P + glyceraldehyde-3-P. Fifteen carbons remain fifteen carbons. No CO2, NADPH or ATP is generated by this rearrangement itself. The names fructose-6-P and glyceraldehyde-3-P matter because they explain how pentose carbon reconnects with glycolysis.
Choose a demand pattern. Predict whether the model retains pentoses, builds them from glycolytic intermediates, or sends excess pentoses back toward glycolysis.
When ribose demand exceeds the need for NADPH, the reversible reactions can use two fructose-6-P plus one glyceraldehyde-3-P to supply three pentose equivalents. Isomerase and epimerase allow the pentose pool to support ribose supply. Oxidative decarboxylation is not obligatory for every newly made ribose.
When both outputs are needed in the oxidative ratio, one G6P supplies one pentose and two NADPH. When NADPH demand is greater, excess pentoses can return as fructose-6-P and glyceraldehyde-3-P. These products may enter glycolysis or, where the necessary reactions and conditions permit, contribute to carbon recycling. A model of one passage must not promise unlimited cycling in every cell.
Does a TPP-responsive defect directly block the two oxidative reductions?
No. It implicates transketolase-mediated rearrangement. A controlled preparation can still generate NADPH through intact oxidative enzymes.
Transfer. Thiamine deficiency also affects other enzymes, including pyruvate dehydrogenase. Neurologic disease cannot be reduced to osmotic accumulation of PPP sugars. A transketolase experiment isolates one function; an ill patient does not have that experimental isolation.
Recycling protection during an oxidant challenge
Mature red cells depend on the oxidative PPP for NADPH supply. They have no mitochondria and cannot replace unstable proteins by new protein synthesis. Their susceptibility reflects their actual enzyme repertoire and cell age, not a rule that every nonmitochondrial compartment lacks other NADPH-producing reactions. [2]
Reduced glutathione, GSH, provides electrons to glutathione peroxidase during peroxide reduction. Two GSH become oxidized glutathione, GSSG. Glutathione reductase uses NADPH to regenerate two GSH from GSSG. The peroxidase consumes GSH; the reductase restores it. Measuring a starting pool is different from measuring its ability to recycle under stress.
Glutathione is not the entire red-cell defense system. Catalase and peroxiredoxin 2 also participate in peroxide handling. NADPH-dependent reducing systems help recycle oxidized peroxiredoxin. Cheah and colleagues found impaired peroxiredoxin recycling after an experimental oxidant challenge in G6PD-deficient neonatal cells. That result supports a broader defense network, not a universal percentage of protection. [6]
Compare adequate supply with supply limitation or a downstream reductase block. Predict which pool fails to recover after the same conceptual challenge.
The model compares directions only. Its pool symbols have no concentration, clinical cutoff, elapsed time, oxidant dose or hemolysis probability. In real blood, oxidant identity, exposure, enzyme activity, red-cell age and other defenses all influence injury. Normal resting values do not establish adequate reserve under a later challenge. The donor study by Francis and colleagues also distinguishes fresh-cell abnormalities from changes during refrigerated storage. [4]
Oxidative injury can denature hemoglobin into Heinz bodies. Supravital preparations help demonstrate these inclusions; a routine smear without visible inclusions does not exclude them. Splenic processing of damaged cells can produce bite cells. These findings support oxidant damage but do not, by themselves, identify which enzyme is deficient.
Follow how precipitated hemoglobin can leave a splenic pit in a red cell.
Would supplying NADPH to a cell-free mixture bypass a missing glutathione reductase?
No. The electron donor cannot replace the enzyme that transfers its electrons to GSSG.
Transfer. A red cell can have preserved glycolytic ATP yet poor redox recovery. Conversely, low ATP from a glycolytic defect does not establish defective NADPH supply. Ask which measured function is impaired before naming a disorder.
The same donor serves different enzymes
NADPH and NADH are chemically related but enzyme recognition separates their functions. NADH participates prominently in energy metabolism and in reduction of pyruvate to lactate. NADPH supports reductive biosynthesis and antioxidant systems. Their similar names do not make them interchangeable substrates for a purified enzyme.
Fatty acid and cholesterol synthesis consume reducing equivalents. Steroidogenic tissue and lactating mammary tissue also have important NADPH demands. Microsomal cytochrome P450 systems receive electrons through NADPH-dependent reductase. These demands help explain tissue use of the PPP without establishing a fixed ranking of all organs.
Some nucleated cells also generate cytosolic NADPH through malic enzyme 1 or isocitrate dehydrogenase 1. Chen and colleagues demonstrated compensation in engineered cultured cells after G6PD deletion. Alternative supply depends on the cell and condition. Neither the existence of mitochondria nor a preserved whole-cell pool proves that the relevant cytosolic compartment is adequately supplied. [5]
If a cultured cell retains NADPH after G6PD inhibition, what must be checked before applying that result to red cells?
Identify the alternative NADPH-producing reactions actually present and active in each cell type.
Neutrophil NADPH oxidase uses NADPH to generate superoxide for host defense. Chronic granulomatous disease, CGD, concerns deficient oxidase activity or assembly, rather than simply a shortage of PPP substrate. CYBB encodes the catalytic gp91phox component; other oxidase defects can be autosomal recessive. Recurrent infections and inflammatory granulomas belong to this clinical pattern. They are not proof of deficient red-cell NADPH. [7]
Dihydrorhodamine, DHR, testing assesses stimulated oxidative function. Abnormal results need context because myeloperoxidase deficiency can also affect this assay. Direct superoxide or NBT findings and molecular testing may help distinguish causes. A supplied normal NADPH concentration plus absent superoxide production localizes differently from a low NADPH supply with intact oxidase.
Transfer. Increasing substrate helps only if substrate is limiting. It cannot repair an absent catalytic protein. That distinction connects an experimental rescue to a clinical mechanism without assuming every oxidative test measures the same step.
A normal result can describe a selected population
In G6PD deficiency, an infection, fava exposure or certain medications may precede hemolysis. Falling hemoglobin, indirect hyperbilirubinemia and increased LDH support red-cell destruction; low haptoglobin and hemoglobinuria support an intravascular component. Splenic clearance may coexist. The pattern and clinical severity matter more than forcing every episode into one compartment.
Recent hemolysis can make G6PD activity appear normal. Vulnerable cells have been lost, and young cells with greater activity may be overrepresented. Recent transfusion adds donor cells. Mayo also cautions that marked leukocytosis can interfere. A normal result in these settings does not settle a compatible presentation. Tell the laboratory the sampling context and arrange repeat or complementary testing as appropriate. Do not treat one fixed waiting interval as correct for every assay and patient. [3]
G6PD is X-linked. Heterozygous females may have widely variable expression because X-inactivation creates a mosaic red-cell population. Genotype alone does not reliably predict their enzyme phenotype. A normal baseline hemoglobin does not guarantee tolerance of a new oxidative exposure. Neonatal jaundice warrants prompt clinical assessment; ancestry or age cannot assign a specific variant. [2]
After donor red cells enter the sample, whose enzyme activity contributes to the result?
Both donor and recipient cells contribute, so the aggregate result may mask the recipient's deficiency.
Medication risk is drug- and regimen-specific. CPIC classifies dapsone, rasburicase and tafenoquine as high risk in deficiency. Nitrofurantoin is classified as medium risk; sulfamethoxazole and chloroquine are not interchangeable with the high-risk group. Rasburicase generates hydrogen peroxide during urate oxidation. Tafenoquine is not a routine safe substitute for primaquine in a deficient patient. Use current prescribing guidance for the actual drug and dose. [2]
When clinically significant hemolysis follows a suspected exposure, address the exposure and assess the patient while confirmation proceeds. A potentially misleading normal assay should not justify continuing the suspected cause. Stabilization, anemia assessment and investigation can occur together.
Use three questions. Which product or enzyme function is failing? Which supplied finding distinguishes production from utilization? Does the sample represent the patient's usual red-cell population? This sequence also works when the final diagnosis is not G6PD deficiency.
Apply the pathway to new evidence
These are original educational cases. Experimental quantities are stipulated teaching conditions, not patient predictions. Each case has one best answer and optional worked reasoning.
Case 1
Show answer and explanations for case 1
A. 4 labeled CO2, 4 unlabeled pentoses and 8 NADPH (Best answer)
Carbon 1 leaves during oxidative decarboxylation. Two reductions give eight NADPH from four G6P.
B. 4 unlabeled CO2, 4 labeled pentoses and 8 NADPH (Why this does not fit)
A label on carbon 6 would remain in this single passage. The label is on carbon 1, which becomes CO2.
C. 4 labeled CO2, 4 unlabeled pentoses and 4 NADPH (Why this does not fit)
The first dehydrogenase alone would give one per G6P. Both dehydrogenases are active, so the second adds four NADPH.
D. No labeled CO2, 4 labeled pentoses and 4 NADPH (Why this does not fit)
A nonoxidative route can conserve sugar carbon. The complete oxidative route releases carbon 1 and yields two NADPH per G6P.
Takeaway: Apply two NADPH per completed oxidative passage.
A. Normal reticulocytes make the recipient result definitive (Why this does not fit)
Reticulocytosis is one cause of misleading activity. Recent donor red cells still contribute to the measured activity.
B. The result proves the earlier low activity was transient (Why this does not fit)
Repeat results can be useful when samples are comparable. The recent sample includes transfused cells, so it cannot erase the earlier intrinsic result.
C. Absence of hemolysis establishes tolerance of the proposed drug (Why this does not fit)
It describes the present clinical condition. No; current stability does not establish tolerance of that medication.
D. Donor activity may mask deficiency despite a normal reticulocyte count (Best answer)
The assay samples donor and recipient red cells. Retain the documented deficiency while clarifying the confounded new assay.
Takeaway: A confounded normal assay cannot overturn documented deficiency.
A. Mitochondria directly supply NADPH to every cytosol (Why this does not fit)
The nucleated cell differs from the mature red cell in organelles. Blocking cytosolic ME1 and IDH1, not testing direct mitochondrial NADPH transport, abolished recovery.
B. The nonoxidative PPP generated the recovered NADPH (Why this does not fit)
It remains connected to glucose metabolism. Those rearrangements do not generate NADPH.
C. All nucleated tissues tolerate complete G6PD loss (Why this does not fit)
This cultured line shows partial recovery. One line and condition do not establish every tissue's capacity.
D. ME1/IDH1-dependent compensation operates in this cultured line (Best answer)
Recovery disappears when cytosolic alternative routes are inhibited. It supports compensation in the tested line without assigning it to mature red cells or all tissues.
Takeaway: Tissue-specific evidence is needed before assuming NADPH backup.
A. Net rearrangement can reverse to replenish the pentose pool (Best answer)
Ribose removal creates a pentose sink while glycolytic intermediates are supplied. No; the reversible branch can replenish pentose without oxidative NADPH production.
B. Net oxidative decarboxylation must increase to replenish ribose (Why this does not fit)
It is one source of pentose. Oxidative entry remains disabled.
C. Net pentose disposal must persist because transketolase is irreversible (Why this does not fit)
The extract initially disposed of pentoses. The carbon rearrangements are reversible under the supplied conditions.
D. Net NADPH production must rise in the reversing rearrangement (Why this does not fit)
Both arise from a complete oxidative passage. Only rearrangement is being redirected, and it does not reduce NADP+.
Takeaway: Reversible carbon routing can change without activating oxidative NADPH production.
A. Continue dapsone until a recovery-phase assay confirms deficiency (Why this does not fit)
The new result conflicts with the earlier phenotype. Acute hemolysis can mask activity and the patient already has documented deficiency.
B. Replace dapsone with another high-risk oxidant before assessment (Why this does not fit)
The underlying condition still needs an effective treatment plan. Clinically significant hemolysis needs assessment and an appropriate alternative, not another unassessed oxidant.
C. Dismiss hemolysis because normal enzyme activity outweighs LDH (Why this does not fit)
It measures activity in the current sample. No; the large fall and hemolysis markers demonstrate an acute problem.
D. Stop the suspected drug and urgently assess the anemia while confirming context (Best answer)
Dyspnea with a large hemoglobin fall and hemolysis markers requires prompt assessment. Its acute timing cannot erase the prior deficiency or justify ongoing dapsone exposure.
Takeaway: Address the suspected exposure and illness without waiting for an unconfounded repeat assay.
